comprehensive -WSS

comprehensive

author：knowledge 2025-09-03 09:36:49 - browse：5725

Photo illustration of a checkbook wrapped with lock and chain – hospital and investment coverage from STAT — Alex Hogan/STAT

Hospitals once dove headfirst into venture capital with splashy headlines and attention-grabbing numbers. Now, in an era of flattened margins and exceedingly uncertain returns, many health systems are quietly pulling back.

NewYork-Presbyterian’s venture firm, once managing roughly $40 million in assets, was essentially dissolved, two former employees said, with leaders punting it from the system’s strategy division to innovation, then from innovation to the investment office — a spokesperson described it as being “integrated” into the broader strategy. PitchBook data show no investments after 2020.

Advocate Health Enterprises, meanwhile, the venture firm of a 67-hospital system based in Charlotte, N.C., has lost at least six employees within the past year, including its president, from a staff that once included about a dozen people.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Readout Newsletter: New research from Sanofi, Regeneron, etc.

WSS

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

WATCH: Why do our ears pop?

Eli Lilly to pay $200M for Beam’s stake in gene

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Medicare Advantage enrollment grows 7.1% to 33.4 million people

focus

comprehensive

leisure time

The cancer drug shortage isn’t new — and neither are the solutions

Paying for Covid pills will soon shift to insurers

Medical leaders decry Supreme Court decision on affirmative action

New CMS data security rules will hurt Medicare, Medicaid research

Activists slam private health insurers over coverage restrictions

Measles policy set amid Florida outbreak alarms vaccine proponents

BioMarin wins approval for gene therapy to treat hemophilia A

Researchers tackle phage therapy hurdles for wider adoption

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: XBI biotech index, Akero Therapeutics

hotspot

Testing for cancer recurrence creates a new limbo for patients

FDA has safety concerns on CRISPR

Paying for Covid pills will soon shift to insurers

Surprise medical billing ban raises prices elsewhere

Congress may force more Covid

Weight loss drugs aren’t covered by Obamacare. That may change

hotspot

explore

focus

leisure time